<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344940</url>
  </required_header>
  <id_info>
    <org_study_id>RJBC1401</org_study_id>
    <nct_id>NCT02344940</nct_id>
  </id_info>
  <brief_title>Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer</brief_title>
  <acronym>TTOS</acronym>
  <official_title>Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer: A Randomized, Controlled, Prospective, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety of toremifene and tamoxifen therapy in premenopausal patients with
      operable breast cancer by monitoring gynecological abnormality,blood lipid level,hepatic
      abnormality,estrogen level and perimenopausal symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of ovarian cyst</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>Ovarian cyst is defined as a purely liquid-filled structure that was equal to or exceeded 3 cm in its largest diameter detected by transvaginal ultrasonography.Participants will be required to receive transvaginal ultrasonography every 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of endometrial thickening</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>Endometrial thickness as measured with transvaginal ultrasonography is equal to or exceeded 8mm.Participants will be required to receive transvaginal ultrasonography every 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of female hormones</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>Change of follicle stimulating hormone(FSH),luteinizing hormone(LH),estradiol(E2) as measured every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of blood lipid</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>Change of blood lipid as measured every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of liver function</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>change of blood lipid as measured every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of fatty liver</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>Incidence of fatty liver as examined by liver ultrasound every 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of Kupperman index</measure>
    <time_frame>participants will be followed during the first year of endocrine therapy</time_frame>
    <description>change of Kupperman index as measured every 3 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>toremifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who will be treated with toremifene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients who will be treated with tamoxifen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toremifene</intervention_name>
    <description>patients will take toremifene 60 mg qd.</description>
    <arm_group_label>toremifene</arm_group_label>
    <other_name>Fareston</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>patients will take tamoxifen 10 mg bid.</description>
    <arm_group_label>tamoxifen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged ≥18 years, premenopausal

          2. Histologically confirmed invasive breast cancer by core needle biopsy, hormonal
             receptor positive, defined as estrogen receptor(ER)/progesterone receptor(PR) positive

          3. Patients must have received standard local therapy: normalized modified radical
             mastectomy or breast conserving surgery with negative margin and post-surgical
             radiotherapy. Patient should completed adjuvant therapy according to conditions,
             including adjuvant radiotherapy, neoadjuvant or adjuvant chemotherapy.

          4. Leukocyte ≥ 3*109/L; Platelets ≥ 75*109/L; Serum glutamate oxaloacetate(AST/SGOT) or
             serum glutamic-pyruvic transaminase(ALT/SGPT) &lt;2.5 times of upper limit of normal
             (UNL) range Serum creatinine/blood urea nitrogen(BUN) ≤ upper limit of normal (UNL)
             range; Written informed consent according to the local ethics committee requirements.

          5. Has Eastern Cooperative Oncology Group(ECOG) Performance Score 0-2;

        Exclusion Criteria:

          1. Histologically confirmed hormonal receptor negative.

          2. Have received neoadjuvant/adjuvant endocrine therapy.

          3. With metastatic tumor.

          4. Family history of endometrial cancer or ovarian cancer or any other kind of
             gynecological malignant tumor.

          5. Have already been detected of ovarian abnormality or endometrial thickening by
             transvaginal ultrasound.

          6. With any of complications that will increase sex hormone level: pituitary
             adenoma，ovarian tumor, thymic cancer，etc.

          7. With any of complications that will decrease sex hormone
             level:hyperthyroidism，hypothyroidism，liver cirrhosis，severe malnutrition，Turner's
             syndrome，sex hormone synthetase deficiency, intracranial tumor, pituitary atrophy,
             etc.

          8. Ovarian ablation or suppression

          9. With severe non-malignant co-morbidity that will influence long-term follow up.

         10. With severe hepatic dysfunction, Child-Pugh C.

         11. With severe cardiac dysfunction, New York Heart Association (NYHA) grading III or
             worse.

         12. Known severe hypersensitivity to any drugs in this study;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunwei Shen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kunwei Shen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>operable</keyword>
  <keyword>premenopausal</keyword>
  <keyword>endocrine therapy</keyword>
  <keyword>safety</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>toremifene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Toremifene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

